The Center for Biosimilars® recaps the top 5 articles for the week of June 11, 2018.
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of June 11.
Number 5: HHS Secretary Alex Azar testified before the Senate Committee on Health, Education, Labor, and Pensions on the Trump administration’s blueprint to lower drug prices, but The American College of Rheumatology is raising concerns about some of HHS’s proposals.
Number 4: The FDA has announced the publication of 2 final guidance documents that seek to provide greater clarity on medical product communications.
Number 3: Research presented at the European League Against Rheumatism’s Annual European Congress of Rheumatology, in Amsterdam, Netherlands, finds that, once patients are educated about biosimilars, most are willing to switch.
Number 2: The Senate Judiciary Committee voted 16 to 5 to report the CREATES Act to the Senate floor.
Number 1: Walgreen and Kroger have filed an antitrust suit against Johnson & Johnson and Janssen, alleging unlawful exclusion of biosimilar competition for infliximab.
Finally, last week, our e-newsletter asked whether the FDA’s approval of Fulphila will improve patient access to prophylaxis of febrile neutropenia.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.